ANDROGEN RECEPTOR ANALYSIS IN REFRACTORY PROSTATE CANCER
ANDROGEN RECEPTOR ANALYSIS IN REFRACTORY PROSTATE CANCER
批准号:
2896681
负责人:
MARY ELLEN TAPLIN
金额:
$14.84万
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-08-01 至 2000-09-30
关键词:
androgen inhibitor androgen receptor biopsy bone marrow clinical research cooperative study drug withdrawal gene mutation hormone therapy human genetic material tag human subject human therapy evaluation human tissue male metastasis molecular oncology molecular pathology neoplasm /cancer chemotherapy neoplasm /cancer genetics nucleic acid sequence polymerase chain reaction prognosis prostate neoplasms
中文摘要
说明:(申请人说明)前列腺癌的发病率为
英文摘要
DESCRIPTION: (Applicant's Description) The incidence of prostate cancer is
increasing annually and, in 1997, it is expected that 41,900 men will die
from prostate cancer. Initially, the majority of men with prostate cancer
can be treated successfully by removing testosterone from the system.
However, after a median of 18 months, the disease becomes androgen
independent and starts to regrow in the absence of testosterone. A long
term objective of this project is to study the molecular mechanisms of
androgen independence. The focus of this project will be on the androgen
receptor. The androgen receptor regulates growth in normal prostate cells
and in prostate cancer. In prostate cancer, mutations in the androgen
receptor have been found in androgen independent prostate cancer but are
rare in early stage hormone sensitive cancer. Functional studies of mutant
androgen receptors have shown that mutant receptors have different binding
affinities and specificities for hormones and hormone antagonists. In
particular, the prostate cancer antagonist hydroxyflutamide actually
stimulates some mutant receptors. In addition, it has been observed that
some patients will have a clinical response to discontinuation of
antiandrogen therapy. It is important, therefore, to examine the prevalence
and type of androgen receptor mutations and identify their importance in the
natural history of prostate cancer.
The first aim of this project is to evaluate the frequency and type of
androgen receptor mutations in tumors from patents with advanced androgen
independent prostate cancer. Prostate tumor sample will be obtained from
bone marrow biopsies of patients enrolling on a Cancer and Leukemia Group B
trial designed to study the withdrawal of antiandrogen alone or the
withdrawal of antiandrogen combined with adrenal hormone blockade. This
trial will provide 230 bone marrow samples from which tumor may be obtained
to examine the sequence the androgen receptor. An additional 120 bone
marrow samples will be obtained during the second year from patients
enrolling on a successor trial of secondary oral antiandrogen therapy.
The second aim of this project is to evaluate the association between
receptor mutations and clinical outcomes, including survival and response to
antiandrogen withdrawal and response to secondary oral antiandrogen therapy.
It is hoped that an understanding of molecular changes in the androgen
receptor with clinical correlation may provide insight into the progression
of androgen independence and lead to more durable hormonal therapies.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Efficacy and Mechanisms of Resistance to Neoadjuvant Intensive Androgen Signaling Inhibition
-
批准号:10628272
-
项目类别:
-
资助金额:$49.26万
-
财政年份:2023
-
负责人:MARY ELLEN TAPLIN
-
依托单位:
CANCER AND LEUKEMIA GROUP B
-
批准号:6173199
-
项目类别:
-
资助金额:$11.28万
-
财政年份:1998
-
负责人:MARY ELLEN TAPLIN
-
依托单位:
ANDROGEN RECEPTOR ANALYSIS IN REFRACTORY PROSTATE CANCER
-
批准号:2694469
-
项目类别:
-
资助金额:$17.73万
-
财政年份:1998
-
负责人:MARY ELLEN TAPLIN
-
依托单位:
CANCER AND LEUKEMIA GROUP B
-
批准号:6376659
-
项目类别:
-
资助金额:$9.68万
-
财政年份:1998
-
负责人:MARY ELLEN TAPLIN
-
依托单位:
CANCER AND LEUKEMIA GROUP B
-
批准号:6513410
-
项目类别:
-
资助金额:$10.66万
-
财政年份:1998
-
负责人:MARY ELLEN TAPLIN
-
依托单位:
海外基金